Abstract: The present disclosure relates to aqueous liquid pharmaceutical compositions comprising a) at least one triptan compound, pharmaceutically acceptable salts or hydrates thereof, and b) xylitol.

Abstract: The present disclosure relates to tablets obtainable by compression of a mixture comprising at least 5% by weight of a diluent and granules which comprise a very slightly soluble drug, wherein the granules consist of a core of saccharose beads having (prior to coating) a mean particle size greater than 150? and a coating layer comprising the very slightly soluble drug and at least one film-forming substance of high-molecular weight, as well as a process for manufacturing such tablets wherein the granules consist of a core saccharose beads having (prior to coating) a mean particle size greater than 150? and a coating layer comprising the very slightly soluble drug and at least one film-forming substance of high-molecular weight for the manufacture of tablets by compression of a mixture comprising said granules and at least 5% by weight of a diluent.

Abstract: Non-tabletted, individually dosed administration forms comprising a composition of at least one pharmaceutically active substance dissolved or dispersed within a matrix material comprising a mixture of at least 0.2% by weight of a gelatine, at least one stabilising agent and at least one water-soluble alcohol and/or water as a solvent, which composition is plastic at elevated temperature, characterised in that: the stabilising agent is chosen from (i) esters of glycerine and fatty acids; (ii) products resulting from the alcoholysis/esterification reaction of such esters of glycerine and fatty acids with polyethylenglycols; in that the stabilising agent has a melting point in the range of 42° C. to 63° C.; and in that water is present in an amount not greater than 46% by weight of the composition.